希罗达治疗老年晚期耐药乳腺癌的临床观察

Clinical Study of Xeloda in Treatment of Drug Resistant Advanced Breast Cancer in Elderly Patients

目的观察希罗达治疗蒽环类紫杉类耐药的老年晚期乳腺癌患者的临床疗效。方法希罗达每日2500mg/m2,分2次,口服14d,21d为一周期,治疗4～6周期。结果32例患者共化疗172个周期,总有效率为28.1%(9/32),临床获益率(CR+PR+SD)为71.9%(23/32)。不良反应以手足综合症、腹泻、口腔炎常见,但均可耐受。结论希罗达治疗蒽环类紫杉类耐药的老年晚期乳腺癌患者安全性好,可获得较好的疗效,且能延长患者生存期,改善生活质量。

Objective To observe the clinical effect of Xeloda （Capecitabine） in treatment of anthracycline and paclitaxel resistant advanced breast cancer in elderly patients. Methods The patients were given Xeloda at a dose of 2 500 mg/（m2·day） divided into twice daily doses for 14 days of 21-day cycle, The treatment lasted for4 -6 cycles. Results Thirty-two patients received 172 cycles of chemotherapy with Xeloda. Overall response rate was 28, 1% （9/32）. The clinical benefit response rate （CR ＋ PR ＋ SD） was 71,9% （23/32）. The common side effects including hand-foot syndrome,diarrhea and stomatitis were tolerable. Conclusions Xeloda is safety and effective for elderly patients with anthracycline and paclitaxel resistant advanced breast cancer, could elongate survival time of patients and improve life quality.